Eureka’s co-authored paper “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1,” was published on Monday in Nature Biotechnology.  The paper describes a bispecific antibody against intracellular antigen (WT-1) that can cross-prime T cells against new antigens, thus spreading epitopes.  The study was performed in collaboration with  Memorial Sloan Kettering Cancer Center.

Read the article here:

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.